Compare Abeona Therapeutics Inc (ABEO) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Skyworks Solutions Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Skyworks Solutions Inc trades at $69.65 (market cap $10.28B). The key difference: Skyworks Solutions Inc is far larger — about 24.4× Abeona Therapeutics Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SWKS | |
|---|---|---|
Market Cap | $421.19M | $10.28B |
Sector | Health | Technology |
52-Week High | $7.45 | $83.40 |
52-Week Low | $4.17 | $52.50 |
Enterprise Value | $276.10M | $10.16B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Skyworks Solutions (SWKS) trades at $69.82, up 1.5% today, with a bullish technical signal and strong recent earnings beats. The company reported Q3 2026 EPS of $1.08, exceeding expectations, driven by broad markets and AI data center growth. However, revenue and net income have trended downward from 2022 peaks. Analyst consensus is a Buy (58.34%), with a $66.00 price target, though the current price exceeds this. The pending Qorvo combination is a key strategic focus.
The outlook is mixed; solid execution and the Qorvo deal offer long-term potential, but near-term revenue contraction, margin pressure, and a recent SEC investigation pose risks. The stock's valuation appears full relative to earnings growth, suggesting cautious optimism is warranted amid integration uncertainties and macroeconomic headwinds affecting the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
